HUP0000921A2 - Thyromimetikus elhízás elleni szerek - Google Patents

Thyromimetikus elhízás elleni szerek

Info

Publication number
HUP0000921A2
HUP0000921A2 HU0000921A HUP0000921A HUP0000921A2 HU P0000921 A2 HUP0000921 A2 HU P0000921A2 HU 0000921 A HU0000921 A HU 0000921A HU P0000921 A HUP0000921 A HU P0000921A HU P0000921 A2 HUP0000921 A2 HU P0000921A2
Authority
HU
Hungary
Prior art keywords
group
atom
cycloalkyl
hydrogen atom
alkyl group
Prior art date
Application number
HU0000921A
Other languages
English (en)
Inventor
Peter Cornelius
Diane Marie Hargrove
Bradley Paul Morgan
Andrew Gordon Swick
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0000921D0 publication Critical patent/HU0000921D0/hu
Publication of HUP0000921A2 publication Critical patent/HUP0000921A2/hu
Publication of HUP0000921A3 publication Critical patent/HUP0000921A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

A találmány tárgyát az (I) általános képletű vegyületek és azokgyógyászatilag elfogadható sói, racemátjai és enantiomerjei és azezeket tartalmazó gyógyszerkészítmények képezik, amelyeknél aképletben R jelentése hidroxi-csoport, észterezett hidroxi-csoportvagy éterezett hidroxi-csoport, R1 és R2 jelentése halogénatom,trifluor-metil-csoport vagy -alkilcsoport, R3 jelentése halogénatom,trifluor-metil-csoport, a1kil-, alkanoil-, hidroxi-alkil-, aril-,aril-alkil-, cikloalkil- vagy cikloalkil-, karbociklusos aril-metil-,karbociklusos aril- vagy karbociklusos aril-hidroxi-metil-csoport,vagy R3 jelentése egy (a) általános képletű csoport, amelyben R8jelentése hidrogénatom, alkil-, cikloalkil-, aril-alkil vagycikloalkil-csoport, R9 jelentése hidroxi- vagy acil-oxi-csoport, R10jelentése hidrogénatom vagy alkilcsoport, vagy R9 és R10 a hozzájukkapcsolódó szénatommal együtt egy karbonil-csoportot alkotnak, R4jelentése hidrogénatom, halogénatom; trifluor-metil-csoport vagyalkilcsoport, R5 és R6 jelentése hidrogénatom vagy alkilcsoport, vagyR5 és R6 a hozzájuk kapcsolódó szénatommal együtt karbonilcsoportotalkotnak, X jelentése oxigénatom, kénatom vagy NR7 általános képletűcsoport ahol R7 jelentése hidrogénatom vagy kis szénatomszámúalkilcsoport, W jelentése oxigénatom vagy kénatom, és Z jelentésekarboxilcsoport vagy gyógyászatilag elfogadható észter- illetve amid-formában jelenlévő karboxil-csoport származék. Ó
HU0000921A 1999-03-01 2000-02-28 Thyromimetic antiobesity agents HUP0000921A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12201599P 1999-03-01 1999-03-01

Publications (3)

Publication Number Publication Date
HU0000921D0 HU0000921D0 (en) 2000-04-28
HUP0000921A2 true HUP0000921A2 (hu) 2000-12-28
HUP0000921A3 HUP0000921A3 (en) 2004-06-28

Family

ID=22400061

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000921A HUP0000921A3 (en) 1999-03-01 2000-02-28 Thyromimetic antiobesity agents

Country Status (15)

Country Link
US (2) US6344481B1 (hu)
EP (1) EP1036564B1 (hu)
JP (1) JP2000256190A (hu)
KR (1) KR100368354B1 (hu)
AT (1) ATE282410T1 (hu)
AU (1) AU1635300A (hu)
CA (1) CA2299972C (hu)
CO (1) CO5150235A1 (hu)
DE (1) DE60015831T2 (hu)
ES (1) ES2233282T3 (hu)
HU (1) HUP0000921A3 (hu)
IL (1) IL134382A0 (hu)
NZ (1) NZ503122A (hu)
PE (1) PE20001539A1 (hu)
ZA (1) ZA200001000B (hu)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
WO2002081751A2 (en) * 2001-04-03 2002-10-17 The Regents Of The University Of California A method of increasing endogenous leptin production
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7829552B2 (en) * 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
EP1730310A2 (en) * 2004-03-22 2006-12-13 The Regents Of The University Of California A formulation for increasing endogenous adiponectin and leptin production
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
WO2007132475A1 (en) * 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
WO2010049946A2 (en) 2008-10-27 2010-05-06 Cadila Healthcare Limited Thyroid receptor ligands
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
CN102459185B (zh) 2009-04-20 2015-06-03 田边三菱制药株式会社 新型甲状腺激素β受体激动剂
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9401828B2 (en) 2010-05-20 2016-07-26 Kandou Labs, S.A. Methods and systems for low-power and pin-efficient communications with superposition signaling codes
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2018226604A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
JP7360583B2 (ja) 2017-09-14 2023-10-13 国立研究開発法人理化学研究所 網膜組織の製造方法
EP3768690A4 (en) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. CRYSTALLINE SHAPES AND METHOD FOR MAKING CRYSTALLINE SHAPES OF A COMPOUND
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
KR20210138639A (ko) 2019-03-13 2021-11-19 다이니뽄 스미토모 세이야쿠 가부시키가이샤 이식용 신경 망막의 품질을 평가하는 방법 및 이식용 신경 망막 시트
JPWO2022054924A1 (hu) 2020-09-11 2022-03-17
EP4206321A4 (en) 2020-09-11 2024-05-01 Riken COMPLEX CONTAINING CELLULAR AGGREGATES CONTAINING NEURAL RETINA, MATRIX AND METHOD OF MANUFACTURING

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315739B2 (hu) * 1973-10-30 1978-05-26
JPS50124993A (hu) * 1974-03-20 1975-10-01
JPS5937018B2 (ja) * 1978-06-16 1984-09-07 株式会社トクヤマ 難燃化ポリプロピレン組成物
ZA824382B (en) 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
GB8519154D0 (en) 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8714901D0 (en) 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
ATE159515T1 (de) 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel
JPH0834976A (ja) * 1994-07-25 1996-02-06 Asahi Denka Kogyo Kk 潜熱利用型蓄熱材
CA2215387A1 (en) * 1995-03-20 1996-09-26 Michael R. Briggs Modulators of ob gene and screening methods therefor
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
CZ20013117A3 (cs) * 1999-03-01 2002-06-12 Pfizer Products Inc. Oxamové kyseliny a jejich deriváty jako ligandy thyreoidního receptoru
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents

Also Published As

Publication number Publication date
NZ503122A (en) 2001-11-30
ZA200001000B (en) 2001-08-29
IL134382A0 (en) 2001-04-30
US6555578B2 (en) 2003-04-29
EP1036564A1 (en) 2000-09-20
US6344481B1 (en) 2002-02-05
HUP0000921A3 (en) 2004-06-28
EP1036564B1 (en) 2004-11-17
DE60015831T2 (de) 2005-12-15
DE60015831D1 (de) 2004-12-23
HU0000921D0 (en) 2000-04-28
CA2299972C (en) 2003-08-19
AU1635300A (en) 2000-09-07
KR100368354B1 (ko) 2003-01-24
KR20010006712A (ko) 2001-01-26
ES2233282T3 (es) 2005-06-16
PE20001539A1 (es) 2001-01-08
CO5150235A1 (es) 2002-04-29
CA2299972A1 (en) 2000-09-01
ATE282410T1 (de) 2004-12-15
US20020035153A1 (en) 2002-03-21
JP2000256190A (ja) 2000-09-19

Similar Documents

Publication Publication Date Title
HUP0000921A2 (hu) Thyromimetikus elhízás elleni szerek
MY127881A (en) Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
NO20025590D0 (no) Fenylglycin-derivater
ATE188216T1 (de) Therapeutische mittel für die parkinsonsche krankheit
HUP0103366A2 (hu) Citokin inhibítorként használható amidszármazékok
HUP0301330A2 (hu) 2-Aminokarbonil-9H-purin-származékok
HUP0303652A2 (hu) Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények
HUP0002031A2 (hu) Benzotiofénszármazékok alkalmazása központi idegrendszeri betegségek kezelésére szolgáló gyógyszerkészítmények előállítására
MX9300988A (es) Agentes antineoplasticos de quinobenzoxazina, quinobenzotiazina y pirido-acridina y composicion farmaceutica que los contiene.
HUP0002330A2 (hu) Azetidinilpropilpiperidin-származékok, ezek intermedierjei és tachikinin antagonistaként történő alkalmazásuk
HUP0100680A2 (hu) Indolszármazékok és azokat tartalmazó gyógyszerkészítmények
DE60137835D1 (de) Modifizierte zytokine für krebs therapie
NO892338D0 (no) Middel for insekt- og middbekjempelse.
TW355709B (en) Quinoline carboxylic acid derivative
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
NO971261D0 (no) Kinoksalin-derivater nyttige innen terapi
NZ505200A (en) Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
DE60000978D1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
ATE336487T1 (de) Benzoesaüre derivate und deren verwendung
AR010205A1 (es) Un compuesto farmaceutico
DK0802920T3 (da) Fusacandin-antisvampemidler
PT970042E (pt) 5-hidroximetil-2-aminotetralinas utilizadas como agentes cardiovasculares
HUP0204144A2 (en) N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses
TR199801366T2 (en) �zooksasefem t�revleri.